Atherosclerosis in systemic lupus erythematosus

Research output: Contribution to journalArticle

Abstract

ABSTRACT:: Accelerated atherosclerosis and its long-term sequelae are a major cause of late mortality among patients with systemic lupus erythematosus (SLE). Traditional Framingham risk factors such as hypertension, hypercholesterolemia, diabetes, and smoking do not account in entirety for this risk. SLE specific factors like disease activity and duration, use of corticosteroids, presence of antiphospholipid antibodies, and others are important risk factors. SLE is considered a coronary heart disease; equivalent and aggressive management of all traditional risk factors is recommended. Despite their role in primary and secondary prevention in the general population, statins seem to have no effect on cardiovascular outcomes in adult or pediatric SLE populations. The use of hydroxychloroquine has a cardioprotective effect, and mycophenolate mofetil may reduce cardiovascular events based on basic science data and data from the transplant population. The role of vitamin D supplementation and treatment of hyperhomocysteinemia remain controversial, but due to the safety of therapy and the potential benefit, they remain as optional therapies.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume62
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Systemic Lupus Erythematosus
Atherosclerosis
Population
Mycophenolic Acid
Hydroxychloroquine
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperhomocysteinemia
Antiphospholipid Antibodies
Primary Prevention
Secondary Prevention
Hypercholesterolemia
Vitamin D
Coronary Disease
Adrenal Cortex Hormones
Therapeutics
Smoking
Pediatrics
Hypertension
Transplants
Safety

Keywords

  • Atherosclerosis
  • Autoimmunity
  • Cardiovascular disease
  • SLE
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Atherosclerosis in systemic lupus erythematosus. / Stojan, George; Petri, Michelle.

In: Journal of Cardiovascular Pharmacology, Vol. 62, No. 3, 09.2013, p. 255-262.

Research output: Contribution to journalArticle

@article{8c9292acd0cc495c903e9baf1bf57973,
title = "Atherosclerosis in systemic lupus erythematosus",
abstract = "ABSTRACT:: Accelerated atherosclerosis and its long-term sequelae are a major cause of late mortality among patients with systemic lupus erythematosus (SLE). Traditional Framingham risk factors such as hypertension, hypercholesterolemia, diabetes, and smoking do not account in entirety for this risk. SLE specific factors like disease activity and duration, use of corticosteroids, presence of antiphospholipid antibodies, and others are important risk factors. SLE is considered a coronary heart disease; equivalent and aggressive management of all traditional risk factors is recommended. Despite their role in primary and secondary prevention in the general population, statins seem to have no effect on cardiovascular outcomes in adult or pediatric SLE populations. The use of hydroxychloroquine has a cardioprotective effect, and mycophenolate mofetil may reduce cardiovascular events based on basic science data and data from the transplant population. The role of vitamin D supplementation and treatment of hyperhomocysteinemia remain controversial, but due to the safety of therapy and the potential benefit, they remain as optional therapies.",
keywords = "Atherosclerosis, Autoimmunity, Cardiovascular disease, SLE, Systemic lupus erythematosus",
author = "George Stojan and Michelle Petri",
year = "2013",
month = "9",
doi = "10.1097/FJC.0b013e31829dd857",
language = "English (US)",
volume = "62",
pages = "255--262",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Atherosclerosis in systemic lupus erythematosus

AU - Stojan, George

AU - Petri, Michelle

PY - 2013/9

Y1 - 2013/9

N2 - ABSTRACT:: Accelerated atherosclerosis and its long-term sequelae are a major cause of late mortality among patients with systemic lupus erythematosus (SLE). Traditional Framingham risk factors such as hypertension, hypercholesterolemia, diabetes, and smoking do not account in entirety for this risk. SLE specific factors like disease activity and duration, use of corticosteroids, presence of antiphospholipid antibodies, and others are important risk factors. SLE is considered a coronary heart disease; equivalent and aggressive management of all traditional risk factors is recommended. Despite their role in primary and secondary prevention in the general population, statins seem to have no effect on cardiovascular outcomes in adult or pediatric SLE populations. The use of hydroxychloroquine has a cardioprotective effect, and mycophenolate mofetil may reduce cardiovascular events based on basic science data and data from the transplant population. The role of vitamin D supplementation and treatment of hyperhomocysteinemia remain controversial, but due to the safety of therapy and the potential benefit, they remain as optional therapies.

AB - ABSTRACT:: Accelerated atherosclerosis and its long-term sequelae are a major cause of late mortality among patients with systemic lupus erythematosus (SLE). Traditional Framingham risk factors such as hypertension, hypercholesterolemia, diabetes, and smoking do not account in entirety for this risk. SLE specific factors like disease activity and duration, use of corticosteroids, presence of antiphospholipid antibodies, and others are important risk factors. SLE is considered a coronary heart disease; equivalent and aggressive management of all traditional risk factors is recommended. Despite their role in primary and secondary prevention in the general population, statins seem to have no effect on cardiovascular outcomes in adult or pediatric SLE populations. The use of hydroxychloroquine has a cardioprotective effect, and mycophenolate mofetil may reduce cardiovascular events based on basic science data and data from the transplant population. The role of vitamin D supplementation and treatment of hyperhomocysteinemia remain controversial, but due to the safety of therapy and the potential benefit, they remain as optional therapies.

KW - Atherosclerosis

KW - Autoimmunity

KW - Cardiovascular disease

KW - SLE

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84884672267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884672267&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e31829dd857

DO - 10.1097/FJC.0b013e31829dd857

M3 - Article

VL - 62

SP - 255

EP - 262

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -